transplant immunosuppressants
Maintenance = CNI (tacrolimus first line) + antiproliferative (mycophenolate first line) ± prednisone (KDIGO 2009). Induction with basiliximab (ATG if high risk). CNIs and mTORi have narrow windows and are CYP3A4/P-gp substrates: drug interactions cause both toxicity and rejection.
mechanism
CNIs block calcineurin → ↓ IL-2 transcription. Mycophenolate inhibits IMPDH (lymphocyte purine synthesis). mTORi block IL-2-driven proliferation. Belatacept blocks CD80/86 co-stimulation. Basiliximab: anti-CD25 (IL-2 receptor).
agents
| drug | monitoring | signature toxicities |
|---|---|---|
| tacrolimus | 12-h trough (KDIGO 2C); usual targets about 7–12 µg/L in year 1, about 5–8 µg/L later (centre protocols; not in KDIGO) | nephrotoxicity (afferent vasoconstriction, chronic fibrosis), tremor, headache, hyperkalaemia, hypomagnesaemia, type 4 RTA, post-transplant diabetes, hypertension, TMA |
| ciclosporin | C0, C2 or abbreviated AUC (2D) | as tacrolimus + gum hyperplasia, hirsutism; more hypertension and dyslipidaemia, less diabetes |
| mycophenolate (MMF/MPA) | CBC; KDIGO suggests monitoring MPA levels (2D) | leucopenia, GI upset/diarrhoea; teratogenic → switch to azathioprine before conception |
| azathioprine | CBC; TPMT before starting | myelosuppression (allopurinol/febuxostat interaction → toxicity); pregnancy-compatible |
| prednisone | glucose, BP, bone | diabetes, weight, osteoporosis, cataracts |
| sirolimus / everolimus | trough (2C) | proteinuria, mouth ulcers, impaired wound healing, lymphocele, pneumonitis, dyslipidaemia, cytopenias; less skin cancer → used for conversion; start only after wounds heal (1B) |
| belatacept | monthly IV | more early rejection; contraindicated if EBV-seronegative (CNS PTLD); better long-term eGFR than ciclosporin |
key points
- CNI interactions (CYP3A4/P-gp):
| raise CNI/mTORi levels → toxicity | lower levels → rejection |
|---|---|
| azoles (fluconazole, voriconazole, posaconazole), clarithromycin/erythromycin, diltiazem, verapamil, protease inhibitors (ritonavir), grapefruit, amiodarone | rifampin, phenytoin, carbamazepine, phenobarbital, St John’s wort |
- Azithromycin is the safe macrolide; amlodipine is the safer CCB
- Hyperkalaemia on tacrolimus: CNI → NCC activation (WNK–SPAK) → volume expansion, low renin/aldosterone → thiazide corrects it → potassium disorders
- Measure CNI levels every other day early, with any interacting drug change, and with every unexplained Cr rise (KDIGO 1B/2C)
- High CNI trough + tremor + Cr rise = toxicity. Low or erratic troughs late = non-adherence (leading cause of late rejection)
- Sustained BK viraemia → reduce maintenance immunosuppression (tacrolimus, mycophenolate) → transplant nephrology
- Trimethoprim (PJP prophylaxis) raises Cr by blocking secretion, without GFR loss
- Glomerular disease (LN, FSGS, MN) uses the same drugs at different targets → glomerular diseases, nephrotic syndrome
Mycophenolate (and mTORi) → stop at least 6 weeks (1.5 months) before conception; switch to azathioprine (EULAR 2024). Tacrolimus, ciclosporin, azathioprine and prednisone are compatible.
adverse effects (class)
- Infection: CMV, BK, PJP, EBV-PTLD → transplant nephrology
- Malignancy: skin cancer (squamous) far above population rates; PTLD
- Metabolic: diabetes (tacrolimus, steroids), dyslipidaemia (mTORi, ciclosporin), hypertension
Prepared 2026-11-01. Not yet verified — check every number against the sources.